Long term use of lokivetmab (Cytopoint®) in atopic dogs
Abstract Lokivetmab (Cytopoint®, Zoetis) has been shown to be effective for the short-term treatment of dogs with allergic and atopic dermatitis but there are no studies at US label dosing (at least 2 mg/kg every 4–8 weeks as necessary) which evaluate long-term usage. The objective of this study was...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | BMC Veterinary Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12917-025-04645-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|